



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known			
		Application Number	10/037,791		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Filing Date	January 3, 2002		
		First Named Inventor	Stanley M. Crain		
		Group Art Unit	1614		
		Examiner Name	James H. Reamer		
Sheet	1	of	3	Attorney Docket Number	96700/727

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	1	Request for Ex Parte Reexamination of U.S. Patent No. RE 36,547.	
	2	Request for Ex Parte Reexamination of U.S. Patent No. 5,767,125.	
	3	Request for Ex Parte Reexamination of U.S. Patent No. 5,580,876.	
	4	Request for Ex Parte Reexamination of U.S. Patent No. 6,362,194	
	5	Request for Ex Parte Reexamination of U.S. Patent No. 6,096,756.	
	6	Dum and Herz, 1981, "In vivo Receptor Binding of the Opiate Partial Agonist, Buprenorphine, Correlated with its Agonistic and Antagonistic Actions," Br. J. Pharmac. 74:627-633.	
	7	Budd, 1987, "Clinical use of opioid antagonists," Balliere's Clinical Anesthesiology 1(4):993-1011.	
	8	Goodman & Gilman, 1975, The Pharmacological Basis of Therapeutics, 5th Edition, Macmillan, New York, Chapter 15, p. 273.	
	9	Crain & Shen, 1995, Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic co-treatment. Proc. Natl. Acad. Sci. U.S.A. 1995 Nov. 7;92(23):10540-10544.	
	10	Konieczko et al. 1988, "Antagonism of morphine-induced respiratory depression with nalmeferene," Br. J. Anaesth. 61:318-323.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/037,791
Sheet	2	of	3
		Filing Date	January 3, 2002
		First Named Inventor	Stanley M. Crain
		Group Art Unit	1614
		Examiner Name	James H. Reamer
		Attorney Docket Number	96700/727

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
	11	Barsan et al. 1989, "Duration of Antagonistic Effects of Nalmefene and Naloxone in Opiate-induced Sedation for Emergency Department Procedures," J. Emerg. Med. 7(2): 155-161.	
	12	Abu-Elheiga et al. 2001, "Continuous fatty acid oxidation and reduced fat storage in mice lacking Acetyl-coA carboxylase 2," Science 291:2613-16.	
	13	Goodman & Gilman (eds.), 1975, The Pharmacological Basis of Therapeutics, 5th Edition, Macmillan, New York, Chapter 15, "Narcotic Analgesics and Antagonists" (by J.H. Jaffe and W.R. Martin) pages 245-283.	
	14	Budd K., 1985, "The use of the opiate antagonist, naloxone, in the treatment of intractable pain." Neuropeptides. 5(4-6):419-22.	
	15	Attal et al. 1989, "Behavioural evidence for a bidirectional effect of systemic naloxone in a model of experimental neuropathy in the rat." Brain Res. 494(2):276-84.	
	16	Kayser et al. 1981, "Dose-dependent analgesic and hyperalgesic effects of systemic naloxone in arthritic rats." Brain Res. 226(1-2):344-8.	
	17	Kayser et al. 1984, "Further evidence for a bidirectional effect of naloxone on the pain threshold in tolerant and non-tolerant arthritic rats." Neuropeptides. 5(1-3):49-52.	
	18	Malaise & Franchimont, 1987, "Methods of clinical and biological assessment of rheumatoid arthritis." Scand. J. Rheumatol. Suppl. 65:81-4, Review.	
	19	Specification of US Patent No. RE 36,547.	

Examiner Signature	Date Considered
---------------------------	------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

